[{"id":"13f962ad-4e51-40e4-943d-c2f1a42f8f88","acronym":"","url":"https://clinicaltrials.gov/study/NCT02327468","created_at":"2021-01-18T11:02:43.451Z","updated_at":"2024-07-02T16:37:16.072Z","phase":"Phase 1","brief_title":"Inovio TRT-001: Telomerase DNA Immunotherapy in Breast, Lung, and Pancreatic Cancers","source_id_and_acronym":"NCT02327468","lead_sponsor":"Inovio Pharmaceuticals","biomarkers":" PGR • CD8 • PTPRC • FOXP3","pipe":" | ","alterations":" HER-2 negative","tags":["PGR • CD8 • PTPRC • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e rocakinogene sifuplasmid (INO-9012) • INO-1400"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 12/01/2014","start_date":" 12/01/2014","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 04/01/2018","study_completion_date":" 04/01/2018","last_update_posted":"2017-11-24"}]